Drug Trial Radar · NCT07511218
A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Apr 13, 2026
Primary completion
Dec 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Ausper Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of AHB-171 Injection in healthy participants (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in CHB participants.
Conditions
- Chronic Hepatitis B Infection
Interventions
AHB-171 InjectionDrug
AHB-171 Injection is adminstrated via subcutaneous injection
PlaceboDrug
Placebo is admistrated via subcutaneous injection
Nucleos(t)ide Analogue (NA)Drug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A & Part B Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
- Severity of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
- Change from baseline in laboratory testsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
- Change from baseline in physical examinationsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
- Change from baseline in vital signsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
- Change from baseline in electrocardiograms (ECGs)Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
- Part A:Plasma Cmax of AHB-171Time frame: Up to Day 8
- Part A:Plasma Tmax of AHB-171Time frame: Up to Day 8
- Part A Plasma AUC of AHB-171Time frame: Up to Day 8
- Part A Plasma t1/2 of AHB-171Time frame: Up to Day 8
- Proportion of participants with clinically significant abnormalities in laboratory testsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
- Proportion of participants with clinically significant abnormalities in electrocardiograms (ECGs)Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
- Proportion of participants with physical examinationsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
- Proportion of participants with other vital signsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
AusperBio Investigational Site
Ch’ang-ch’un, Jilin, China · Recruiting
AusperBio Investigational Site
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.